跳至主要内容
临床试验/ISRCTN10706683
ISRCTN10706683进行中(未招募)Unknown

iothyronine to normalise Thyroid Hormones in Heart Failure (T3-HF) - A feasibility study

Gateshead Health NHS Foundation Trust0 个研究点目标入组 25 人开始时间: 2023年9月29日最近更新:

试验速览

阶段
Unknown
状态
进行中(未招募)
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Men and women aged between 18 – 80 years
  • 2. Stable HFrEF (no admission to hospital with HF exacerbations in the previous 3 months)
  • 3. Chronic HFrEF (diagnosed more than 3 months prior to recruitment)
  • 4. Moderate – severe systolic left ventricular dysfunction (LVEF < 45% on cardiac echocardiogram within last 6 months)
  • 5. On standard HFrEF therapy
  • 6. With low serum T3 levels (< 3.5 pmol/L)

排除标准

  • 1. Those on medications affecting thyroid function (such as levothyroxine, antithyroid drugs, amiodarone, lithium and sodium valproate)
  • 2. Patients admitted to hospital with acute exacerbation of HF in the preceding 3 months
  • 3. Claustrophobia precluding cardiac magnetic resonance (MR) assessment
  • 4. Cardiac devices (such as implantable cardioverter defibrillators) that are incompatible with MR scanning
  • 5. Untreated valvular heart disease as the main cause of the HFrEF
  • 6. With severely abnormal serum TSH (< 0.1 or > 10.0 mIU/L) or thyroxine (FT4) levels (< 9.0 or > 23.0 pmol/L)
  • 7. Participants who are unable to provide written informed consent
  • 8. Individuals who are pregnant or trying to conceive

研究者

相似试验